NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCR NovoCure

Post-Mkt 08-19 18:46:44 EDT

18.20

+0.96

+5.57%

盘后18.33

+0.13+0.71%

18:44 EDT

High18.34	Low17.38	Vol4.84M
Open17.40	D1 Closing17.24	Amplitude5.57%
Mkt Cap2.12B	Tradable Cap1.75B	Total Shares116.45M
T/O87.03M	T/O Rate5.02%	Tradable Shares96.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCR","market":"US","secType":"STK","nameCN":"NovoCure","latestPrice":18.2,"timestamp":1787169600000,"preClose":17.24,"halted":0,"volume":4838224,"hourTrading":{"tag":"盘后","latestPrice":18.33,"preClose":18.2,"latestTime":"18:44 EDT","volume":1590669,"amount":28950161.483979,"timestamp":1787179449812,"change":0.13,"changeRate":0.007143,"amplitude":0.014835},"delay":0,"changeRate":0.055684454756380564,"floatShares":96423600,"shares":116445840,"eps":-1.308249,"marketStatus":"Post-Mkt","change":0.96,"latestTime":"08-19 18:46:44 EDT","open":17.4,"high":18.34,"low":17.38,"amount":87033118.1576,"amplitude":0.055684,"askPrice":18.44,"askSize":99,"bidPrice":17.99,"bidSize":99,"shortable":3,"etf":0,"ttmEps":-1.308249,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787184000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1443758400000,"exchange":"NASDAQ","adjPreClose":17.24,"preHourTrading":{"tag":"盘前","latestPrice":17.4,"preClose":17.24,"latestTime":"09:29 EDT","volume":471,"amount":8237.929887,"timestamp":1787146199700,"change":0.16,"changeRate":0.009281,"amplitude":0.053944},"postHourTrading":{"tag":"盘后","latestPrice":18.33,"preClose":18.2,"latestTime":"18:44 EDT","volume":1590669,"amount":28950161.483979,"timestamp":1787179449812,"change":0.13,"changeRate":0.007143,"amplitude":0.014835},"volumeRatio":5.593796,"impliedVol":0.4362,"impliedVolPercentile":0.0518},"requestUrl":"/m/hq/s/NVCR/tweets","defaultTab":"tweets","newsList":[{"id":"2658961006","title":"NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2658961006","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658961006?lang=en_us&edition=fundamental","pubTime":"2026-08-11 11:36","pubTimestamp":1786419393,"startTime":"0","endTime":"0","summary":"Recent momentum in NovoCure (NVCR) stock has been closely tied to renewed optimism around its tumor treating fields devices and the possibility of upcoming FDA approval, which has kept investor attention firmly on the company.\nSee our latest analysis for NovoCure.\nThat optimism has fed into a strong short term trend for NovoCure, with a 1 day share price return of 5.61% and a 7 day share price return of 12.99%. The 1 year total shareholder return sits at 58.81%, despite a 3 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvda-following-ttfields-optimism-and-fda-approval-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvda-following-ttfields-optimism-and-fda-approval-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4548","BK4082","BK4534","BK4588","NVCR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655417368","title":"NovoCure (NVCR) Stock Looks Undervalued With Shares Down 90% Over Five Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2655417368","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655417368?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:26","pubTimestamp":1785382000,"startTime":"0","endTime":"0","summary":"NovoCure stock is coming off a very difficult five year stretch, with the share price down about 90%, yet the latest valuation checks still lean toward the shares looking cheap on several measures. That contrast, alongside fresh company developments in cancer therapies, is what investors are weighing now.\n\nOver the past five years, NovoCure shares have declined about 90%. As a result, any sign of a sustainable business recovery can have an outsized impact on how the market prices the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-stock-looks-undervalued-with-shares-down-90-ov","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/novocure-nvcr-stock-looks-undervalued-with-shares-down-90-ov","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4548","TACU","NVCR","BK4588","CDIG","TSPA","BK4082","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653033071","title":"NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding","url":"https://stock-news.laohu8.com/highlight/detail?id=2653033071","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653033071?lang=en_us&edition=fundamental","pubTime":"2026-07-24 23:08","pubTimestamp":1784905685,"startTime":"0","endTime":"0","summary":"NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/07/60670817/novocures-strongest-quarter-ever-isnt-enough-to-stop-nvcr-stock-from-sliding","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4585","BK4534","BK4082","BK4588","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653826300","title":"Wedbush Adjusts Price Target on NovoCure to $20 From $18, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2653826300","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653826300?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:33","pubTimestamp":1784896432,"startTime":"0","endTime":"0","summary":"NovoCure (NVCR) has an average rating of overweight and mean price target of $27.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653084583","title":"Novocure price target raised to $20 from $18 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2653084583","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653084583?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:50","pubTimestamp":1784893846,"startTime":"0","endTime":"0","summary":"Wedbush raised the firm’s price target on Novocure (NVCR) to $20 from $18 and keeps a Neutral rating on the shares. The firm notes the company’s Q2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novocure-price-target-raised-to-20-from-18-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novocure-price-target-raised-to-20-from-18-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4588","BK4534","BK4585","NVCR","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653770796","title":"NovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2653770796","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653770796?lang=en_us&edition=fundamental","pubTime":"2026-07-24 10:00","pubTimestamp":1784858400,"startTime":"0","endTime":"0","summary":"TradingKey - NovoCure surged to $19.91 after Q2 2026 earnings released this morning. Revenue consensus was $172M growing 8.6% YoY. The story is Optune Pax's FDA approval and multi-indication expansion after June's TRIDENT trial disappointment. Here is the setup.","market":"sh","thumbnail":"https://resource.tradingkey.com/uploads/20260723/NOVOC-aecb2b8d41fd49429c2166fea0cfdf48.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260723/NOVOC-aecb2b8d41fd49429c2166fea0cfdf48.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262050883-novocure-nvcr-stock-breakout-q2-2026-earnings-optune-pax-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653727428","title":"Novocure is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2653727428","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653727428?lang=en_us&edition=fundamental","pubTime":"2026-07-24 02:01","pubTimestamp":1784829660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings(END) Dow Jones NewswiresJuly 23, 2026 14:01 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4534","BK4585","NVCR","BK4588","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653660722","title":"Novocure price target raised to $52 from $46 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2653660722","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653660722?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:55","pubTimestamp":1784825713,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $52 from $46 and keeps a Buy rating on the shares. The company reported a reco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novocure-price-target-raised-to-52-from-46-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novocure-price-target-raised-to-52-from-46-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4588","BK4534","BK4585","BK4548","NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653725705","title":"Novocure Shares Rise After Co Boosts FY26 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2653725705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653725705?lang=en_us&edition=fundamental","pubTime":"2026-07-23 22:03","pubTimestamp":1784815380,"startTime":"0","endTime":"0","summary":"Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter.The stock was up 26% to $19.59 in recent tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4548","NVCR","BK4534","BK4082","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653072309","title":"Novocure Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2653072309","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653072309?lang=en_us&edition=fundamental","pubTime":"2026-07-23 21:31","pubTimestamp":1784813518,"startTime":"0","endTime":"0","summary":"Novocure Ltd reports results for the quarter ended June 30 - Earnings SummaryNovocure LtdNVCR.OQreported a quarterly adjusted loss of 17 cents per share for the quarter ended June 30, higher than the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nL8N43P1ZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4585","BK4534","BK4082","BK4588","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653723563","title":"Utah Medical Q2 Revenue Falls 14% on Lost Customers","url":"https://stock-news.laohu8.com/highlight/detail?id=2653723563","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653723563?lang=en_us&edition=fundamental","pubTime":"2026-07-23 21:10","pubTimestamp":1784812252,"startTime":"0","endTime":"0","summary":"Utah Medical Q2 revenue falls 14% on lost customersOverviewUS medical device maker's Q2 revenue fell 14% yr/yr due to loss of major customersQ2 diluted EPS declined 10% yr/yr as new sales failed to of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nL1N43P0QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","LU0345770308.USD","FSI","GNMX","LU2092937221.SGD","LU0432979614.USD","LU2089984988.USD","IE0002141913.USD","BK4534","LU1923622614.USD","LU0316494557.USD","LU0823416689.USD","FMED","LU1923622291.USD","LU2125909247.SGD","IE00BQXX3D17.EUR","LU1291159041.SGD","LU0114720955.EUR","LU1548497426.USD","LU1720051017.SGD","NVCR","TMO","TMED","LU0070302665.USD","IE00BFTCPJ56.SGD","LU0266013472.USD","BK4548","LU0528227936.USD","LU1153585028.USD","LU0342679015.USD","LU1023059063.AUD","LU2468319806.SGD","BK4121","LU2360108059.USD","LU2720916845.USD","IE0034235188.USD","LU0122379950.USD","HRTS","LU0557290698.USD","LU0957791311.USD","LU2433249047.HKD","LU2764262908.HKD","LU2764263039.SGD","UTMD","LU1815333072.USD","LU1670627923.USD","LU0234572021.USD","IE00B2B36J28.USD","LU0882574055.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653742919","title":"NovoCure's Q2 Net Loss Narrows, Revenue Rises; 2026 Revenue Guidance Raised","url":"https://stock-news.laohu8.com/highlight/detail?id=2653742919","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653742919?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:37","pubTimestamp":1784806623,"startTime":"0","endTime":"0","summary":"NovoCure  reported a Q2 net loss Thursday of $0.13 per diluted share, narrowing from a loss of $0.36 a year earlier.Analysts polled by FactSet expected a loss of $0.33.Revenue for the quarter ended June 30 was $183.6 million, compared with $158.8 million a year earlier.Analysts polled by FactSet expected $172.4 million.The company has raised 2026 revenue guidance to $710 million to $725 million from the prior guidance of $690 million to $710 million.Analysts polled by FactSet expect $708.7 million.Shares of the company were nearly 11% higher in premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653744154","title":"Novocure Q2 Revenue Beats, Lifts 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2653744154","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653744154?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:13","pubTimestamp":1784805211,"startTime":"0","endTime":"0","summary":"Novocure Q2 revenue beats, lifts 2026 outlookOverviewGlobal oncology firm's Q2 revenue rose 16% yr/yr, beating analyst expectationsCompany posted Q2 net loss of $15.7 mlnRaised 2026 revenue and adjust","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nL1N43P0HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4548","NVCR","BK4588","BK4082","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653974499","title":"Novocure Q2 Revenue USD 183.584 Million Vs. IBES Estimate USD 172.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2653974499","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653974499?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:10","pubTimestamp":1784805051,"startTime":"0","endTime":"0","summary":"Jul 23 (Reuters) - Novocure Q2 operating income USD -10.562 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 23-JUL-202610:45:00.12 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nRSD52Bg46:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NVCR","BK4548","BK4082","BK4585","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653874497","title":"GUIDANCE: (NVCR) NovoCure Expects Full Year 2026 Revenue Range $710M - $725M, vs. FactSet Est of $708.7M","url":"https://stock-news.laohu8.com/highlight/detail?id=2653874497","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653874497?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:10","pubTimestamp":1784805026,"startTime":"0","endTime":"0","summary":"GUIDANCE: (NVCR) NovoCure Expects Full Year 2026 Revenue Range $710M - $725M, vs. FactSet Est of $708.7M","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653874466","title":"Earnings Flash (NVCR) NovoCure Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.33 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2653874466","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653874466?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:10","pubTimestamp":1784805000,"startTime":"0","endTime":"0","summary":"Earnings Flash (NVCR) NovoCure Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.33 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653741728","title":"NovoCure Q2 EPS $(0.13) Beats $(0.33) Estimate, Sales $183.584M Beat $172.437M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2653741728","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653741728?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:01","pubTimestamp":1784804491,"startTime":"0","endTime":"0","summary":"NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.33) by 60.61 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60632317/novocure-q2-eps-0-13-beats-0-33-estimate-sales-183-584m-beat-172-437m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653741023","title":"Novocure Q2 FY26 Net Loss Narrows to USD 15.66 Million; Revenue Rises 16% to USD 183.58 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2653741023","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653741023?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:00","pubTimestamp":1784804459,"startTime":"0","endTime":"0","summary":"Novocure Q2 FY26 net loss narrows to USD 15.66 million; revenue rises 16% to USD 183.58 millionNovocure posted Q2 net revenues up 16% year over year to USD 183.6 million, while net loss narrowed to US","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL6dfyrv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4588","BK4534","BK4585","NVCR","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653744442","title":"Novocure Q2 EPS USD -0.13","url":"https://stock-news.laohu8.com/highlight/detail?id=2653744442","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653744442?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:00","pubTimestamp":1784804401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nPLXDHLD3D:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4588","BK4082","BK4585","NVCR","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653741476","title":"Novocure Q2 Pretax Profit USD -12.452 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2653741476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653741476?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:00","pubTimestamp":1784804401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nPLXDHLD3D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCR","BK4082","BK4534","BK4548","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novocure.com","stockEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":0.0829},{"period":"3month","weight":-0.0287},{"period":"6month","weight":0.5136},{"period":"1year","weight":0.426},{"period":"ytd","weight":0.3333}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.0353},{"period":"6month","weight":0.1212},{"period":"1year","weight":0.193},{"period":"ytd","weight":0.1254}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.026321},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.001726},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.034505},{"month":4,"riseRate":0.545455,"avgChangeRate":0.108267},{"month":5,"riseRate":0.818182,"avgChangeRate":0.133305},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.03448},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006046},{"month":8,"riseRate":0.636364,"avgChangeRate":0.032863},{"month":9,"riseRate":0.4,"avgChangeRate":-0.021376},{"month":10,"riseRate":0.2,"avgChangeRate":-0.091688},{"month":11,"riseRate":0.636364,"avgChangeRate":0.077306},{"month":12,"riseRate":0.545455,"avgChangeRate":0.065178}],"exchange":"NASDAQ","name":"NovoCure","nameEN":"NovoCure"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NovoCure,NVCR,NovoCure股票,NovoCure股票老虎,NovoCure股票老虎国际,NovoCure行情,NovoCure股票行情,NovoCure股价,NovoCure股市,NovoCure股票价格,NovoCure股票交易,NovoCure股票购买,NovoCure股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}